Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Veterans | 7 | 2022 | 2649 | 1.120 |
Why?
|
Colposcopy | 1 | 2024 | 150 | 0.880 |
Why?
|
Biological Therapy | 1 | 2022 | 141 | 0.740 |
Why?
|
Propensity Score | 3 | 2023 | 1913 | 0.690 |
Why?
|
Tobacco Smoke Pollution | 2 | 2023 | 819 | 0.690 |
Why?
|
Inflammatory Bowel Diseases | 3 | 2022 | 2422 | 0.640 |
Why?
|
Veterans Health | 1 | 2019 | 215 | 0.590 |
Why?
|
Group Homes | 4 | 2024 | 59 | 0.560 |
Why?
|
International Classification of Diseases | 1 | 2021 | 910 | 0.500 |
Why?
|
Models, Statistical | 2 | 2020 | 5079 | 0.490 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2024 | 2020 | 0.480 |
Why?
|
Early Detection of Cancer | 5 | 2024 | 3201 | 0.460 |
Why?
|
Biological Products | 1 | 2022 | 914 | 0.410 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5314 | 0.400 |
Why?
|
Colitis, Ulcerative | 1 | 2020 | 1922 | 0.300 |
Why?
|
Public Housing | 2 | 2023 | 140 | 0.240 |
Why?
|
Smoking | 1 | 2019 | 9053 | 0.210 |
Why?
|
Electronic Health Records | 1 | 2020 | 4811 | 0.210 |
Why?
|
Massachusetts | 6 | 2024 | 8833 | 0.200 |
Why?
|
Housing | 2 | 2023 | 670 | 0.190 |
Why?
|
Papillomavirus Infections | 2 | 2024 | 1613 | 0.180 |
Why?
|
United States | 14 | 2024 | 72340 | 0.180 |
Why?
|
Lung Neoplasms | 2 | 2022 | 13381 | 0.180 |
Why?
|
Aged | 17 | 2024 | 169310 | 0.170 |
Why?
|
Medicare Part C | 1 | 2024 | 334 | 0.160 |
Why?
|
Medicare Part D | 1 | 2024 | 355 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 218 | 0.160 |
Why?
|
Amlodipine | 1 | 2018 | 84 | 0.150 |
Why?
|
Hydrochlorothiazide | 1 | 2018 | 94 | 0.150 |
Why?
|
Metoprolol | 1 | 2018 | 90 | 0.150 |
Why?
|
Humans | 37 | 2024 | 761596 | 0.150 |
Why?
|
Gastrointestinal Agents | 1 | 2022 | 510 | 0.140 |
Why?
|
Prescription Drugs | 1 | 2024 | 631 | 0.130 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2022 | 621 | 0.130 |
Why?
|
Sample Size | 1 | 2019 | 841 | 0.130 |
Why?
|
Computer Simulation | 2 | 2020 | 6241 | 0.130 |
Why?
|
United States Department of Veterans Affairs | 1 | 2021 | 928 | 0.130 |
Why?
|
Prenatal Diagnosis | 1 | 2022 | 1265 | 0.120 |
Why?
|
Developmental Disabilities | 1 | 2024 | 1509 | 0.120 |
Why?
|
Fees, Pharmaceutical | 1 | 2015 | 66 | 0.120 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2022 | 942 | 0.120 |
Why?
|
Mental Disorders | 2 | 2024 | 6845 | 0.110 |
Why?
|
Guideline Adherence | 1 | 2024 | 2220 | 0.110 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2019 | 556 | 0.110 |
Why?
|
Medicare | 2 | 2022 | 6770 | 0.110 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2022 | 4352 | 0.110 |
Why?
|
Piperidines | 1 | 2022 | 1656 | 0.110 |
Why?
|
Myocardial Infarction | 3 | 2024 | 11461 | 0.110 |
Why?
|
Melanoma | 2 | 2022 | 5709 | 0.100 |
Why?
|
Hepatitis C | 1 | 2022 | 1584 | 0.100 |
Why?
|
Prognosis | 3 | 2024 | 29629 | 0.100 |
Why?
|
Scopolamine Derivatives | 1 | 2011 | 24 | 0.100 |
Why?
|
ROC Curve | 1 | 2019 | 3578 | 0.100 |
Why?
|
Methylphenidate | 1 | 2015 | 488 | 0.090 |
Why?
|
Smoking Cessation | 1 | 2022 | 2057 | 0.090 |
Why?
|
Comorbidity | 2 | 2022 | 10508 | 0.090 |
Why?
|
Middle Aged | 11 | 2024 | 220921 | 0.090 |
Why?
|
Risk Factors | 9 | 2024 | 74213 | 0.090 |
Why?
|
Pyrimidines | 1 | 2022 | 3028 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1866 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 2018 | 2024 | 0.080 |
Why?
|
Adult | 11 | 2024 | 221210 | 0.080 |
Why?
|
Mortality | 1 | 2019 | 2902 | 0.080 |
Why?
|
Female | 17 | 2024 | 392705 | 0.080 |
Why?
|
Bronchodilator Agents | 1 | 2011 | 512 | 0.070 |
Why?
|
Cohort Studies | 4 | 2024 | 41495 | 0.070 |
Why?
|
Thrombosis | 1 | 2022 | 2942 | 0.070 |
Why?
|
Medical Oncology | 1 | 2019 | 2321 | 0.070 |
Why?
|
Aminopyridines | 1 | 2011 | 573 | 0.070 |
Why?
|
Cardiovascular Diseases | 2 | 2024 | 15502 | 0.070 |
Why?
|
Hospitalization | 2 | 2024 | 10721 | 0.070 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7391 | 0.070 |
Why?
|
HIV Infections | 2 | 2024 | 17354 | 0.070 |
Why?
|
Central Nervous System Stimulants | 1 | 2015 | 1177 | 0.070 |
Why?
|
Benzamides | 1 | 2011 | 1371 | 0.060 |
Why?
|
Male | 13 | 2024 | 360846 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 10212 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2015 | 1998 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2024 | 5127 | 0.060 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 26129 | 0.060 |
Why?
|
Multiple Sclerosis | 1 | 2019 | 3222 | 0.060 |
Why?
|
Drug Delivery Systems | 1 | 2015 | 2226 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2021 | 5146 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20100 | 0.050 |
Why?
|
Patient Selection | 1 | 2015 | 4244 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5841 | 0.050 |
Why?
|
Medication Adherence | 1 | 2015 | 2176 | 0.050 |
Why?
|
Insurance Benefits | 1 | 2024 | 187 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2022 | 64685 | 0.050 |
Why?
|
Hypoglycemic Agents | 1 | 2015 | 3085 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2022 | 80647 | 0.050 |
Why?
|
Stroke | 1 | 2024 | 9758 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2021 | 5821 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2022 | 58984 | 0.050 |
Why?
|
Blood Sedimentation | 1 | 2022 | 235 | 0.050 |
Why?
|
Sweden | 1 | 2024 | 1379 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39106 | 0.040 |
Why?
|
Insulin | 1 | 2015 | 6597 | 0.040 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2015 | 3708 | 0.040 |
Why?
|
California | 1 | 2024 | 1430 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2022 | 422 | 0.040 |
Why?
|
Obesity | 1 | 2022 | 12947 | 0.040 |
Why?
|
Ferritins | 1 | 2022 | 598 | 0.040 |
Why?
|
Vaginal Smears | 1 | 2021 | 499 | 0.040 |
Why?
|
Pandemics | 3 | 2023 | 8656 | 0.040 |
Why?
|
Intracranial Hemorrhages | 1 | 2024 | 822 | 0.040 |
Why?
|
Hypertension | 1 | 2018 | 8540 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2022 | 1596 | 0.040 |
Why?
|
Hospitals, Teaching | 1 | 2022 | 1156 | 0.030 |
Why?
|
SEER Program | 1 | 2022 | 1450 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2023 | 846 | 0.030 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 3204 | 0.030 |
Why?
|
Minority Groups | 1 | 2024 | 1203 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2023 | 21019 | 0.030 |
Why?
|
Nursing Homes | 1 | 2023 | 1082 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2021 | 1119 | 0.030 |
Why?
|
Hepacivirus | 1 | 2022 | 1336 | 0.030 |
Why?
|
Registries | 2 | 2022 | 8225 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1892 | 0.030 |
Why?
|
Disabled Persons | 1 | 2024 | 1226 | 0.030 |
Why?
|
Random Allocation | 1 | 2018 | 2395 | 0.030 |
Why?
|
Aging | 2 | 2022 | 8710 | 0.030 |
Why?
|
Women's Health | 1 | 2022 | 2065 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2021 | 3597 | 0.030 |
Why?
|
Social Class | 1 | 2021 | 2004 | 0.030 |
Why?
|
Mammography | 1 | 2023 | 2430 | 0.030 |
Why?
|
Cerebral Hemorrhage | 1 | 2024 | 2656 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2022 | 3208 | 0.020 |
Why?
|
Antidepressive Agents | 1 | 2024 | 2897 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22173 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2015 | 857 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2015 | 12149 | 0.020 |
Why?
|
Boston | 1 | 2023 | 9327 | 0.020 |
Why?
|
Sex Factors | 1 | 2024 | 10554 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2015 | 709 | 0.020 |
Why?
|
Cyclopropanes | 1 | 2011 | 432 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2022 | 3826 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3060 | 0.020 |
Why?
|
Child Behavior | 1 | 2015 | 847 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2024 | 12463 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2643 | 0.020 |
Why?
|
Risk Assessment | 2 | 2024 | 23996 | 0.020 |
Why?
|
Markov Chains | 1 | 2011 | 966 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2022 | 5293 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2023 | 8002 | 0.020 |
Why?
|
Administration, Oral | 1 | 2015 | 4021 | 0.020 |
Why?
|
Adolescent Behavior | 1 | 2015 | 1190 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8466 | 0.020 |
Why?
|
Health Services | 1 | 2011 | 752 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2019 | 4176 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 22176 | 0.020 |
Why?
|
Mass Screening | 1 | 2021 | 5429 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2015 | 15843 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2021 | 3358 | 0.020 |
Why?
|
Drug Combinations | 1 | 2011 | 2048 | 0.020 |
Why?
|
Time Factors | 2 | 2021 | 39969 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2011 | 1722 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2015 | 5247 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5337 | 0.010 |
Why?
|
Incidence | 1 | 2022 | 21355 | 0.010 |
Why?
|
Adolescent | 2 | 2024 | 88326 | 0.010 |
Why?
|
Child | 2 | 2022 | 80158 | 0.010 |
Why?
|
Pregnancy | 1 | 2022 | 29890 | 0.010 |
Why?
|
Infant | 1 | 2022 | 36193 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15266 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2011 | 5493 | 0.010 |
Why?
|
Health Status | 1 | 2011 | 4077 | 0.010 |
Why?
|
Young Adult | 1 | 2024 | 59260 | 0.010 |
Why?
|
Brain | 1 | 2024 | 27121 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2024 | 36426 | 0.010 |
Why?
|
Concepts
(170)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(56)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_